Prihlásiť sa Zaregistrujte sa zadarmo

1 ročný cieľ spoločnosti Inhibrx

Aká je hodnota metriky 1 ročný cieľ spoločnosti Inhibrx?

Hodnota metriky 1 ročný cieľ spoločnosti Inhibrx, Inc. je $48 +218.87%

Aká je definícia metriky 1 ročný cieľ?

1-ročný cieľ (1-year target) je analytikmi predpokladaná cena akcie za rok od dnešného dňa.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1 ročný cieľ spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx

Čomu sa venuje spoločnosť Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy s metrikou 1 ročný cieľ podobnou spoločnosti Inhibrx